AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01524432
Drug: Anti-fungal agent (Clotrimazole) loaded microcapsules
RxNorm normalized name: Aardora Anti-Fungal Maximum Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
Trial: NCT01524432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug loaded microcapsules socks
Trial: NCT01485900
Drug: SAR407899A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Trial: NCT01167010
Drug: Foraseq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
Trial: NCT03403985
Drug: Calcium Hydroxide (Ca(OH)2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca(OH)2 will be used in this group
Trial: NCT00792662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard inactive pill.
Trial: NCT01316276
Drug: Liposomal amikacin for inhalation
RxNorm normalized name: amikacin liposomal Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment.
Trial: NCT02361424
Drug: PXT00864
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate
Trial: NCT02361424
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02442453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
Trial: NCT03142724
Drug: [18F]MNI-968
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
Trial: NCT01573312
Drug: ASO3 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
Trial: NCT00383643
Drug: Matching Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00218296
Drug: Usual Care Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy
Trial: NCT00990327
Drug: Adenosine SPECT-MPI
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
Trial: NCT01893372
Drug: Hypomethylating Agent (HMA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
Trial: NCT01474590
Drug: doxycycline 200mg
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, 2 capsules once daily in the morning with aglass of water and with food
Trial: NCT02885454
Drug: Drospirenone/ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
Trial: NCT01688947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
Trial: NCT01643850
Drug: MCS110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
Trial: NCT01643850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
Trial: NCT00000419
Drug: Premarin and Provera
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02152059
Drug: BIBF1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
Trial: NCT01015235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infusion-once over 4 hours
Trial: NCT00747487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01960855
Drug: ABT-494
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-494 capsule administered orally twice daily (BID).
Trial: NCT01960855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for ABT-494 capsule administered orally twice daily (BID).
Trial: NCT03488888
Drug: Normal Saline 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
Trial: NCT00387179
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg, pill, once
Trial: NCT00387179
Drug: Methylxanthine
RxNorm normalized name: Methylxanthine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.9 mg/kg, pill, once
Trial: NCT00517439
Drug: RO4588161
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg po bid for 24 weeks
Trial: NCT00517439
Drug: RO4588161
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg po bid for 24 weeks
Trial: NCT00517439
Drug: RO4588161
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500mg po bid for 24 weeks
Trial: NCT01174004
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, tablet, once daily by mouth for 6 weeks
Trial: NCT00037648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03352453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Trial: NCT00858897
Drug: Regular Insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
Trial: NCT04460924
Drug: Integrase strand transfer inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
Trial: NCT01330979
Drug: AR-12286 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution
Trial: NCT02220023
Drug: INOmax Inhalation
RxNorm normalized name: INOmax Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02492945
Drug: 3ml-Rejuvinex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
Trial: NCT04178993
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each arm, subjects will receive placebo capsules.
Trial: NCT02492945
Drug: 3ml-15%-dextrose solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
Trial: NCT04143217
Drug: SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 200 to 600 mg/day
Trial: NCT01962987
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
Trial: NCT04371640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT00607113
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg By Mouth Daily For 21 Days
Trial: NCT04620382
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT01044212
Drug: Bowel medications
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
Trial: NCT02636244
Drug: SHAPE Gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00075387
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00975104
Drug: AMG 745 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 745 0.3 mg/kg IV QW
Trial: NCT00975104
Drug: AMG 745 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 745 1.0 mg/kg IV QW
Trial: NCT00975104
Drug: AMG 745 3.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 745 3.0 mg/kg IV QW
Trial: NCT00975104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV QW
Trial: NCT01082510
Drug: Bacille Calmette-Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
Trial: NCT01082510
Drug: uracil-tegafur
RxNorm normalized name: tegafur / uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
Trial: NCT00915369
Drug: Nanoxel (Paclitaxel Nanoparticle formulation )
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
Trial: NCT00909545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Placebo to Match (PTM) tablets once daily
Trial: NCT04129788
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three doses taken, one per day on three consecutive days
Trial: NCT02076828
Drug: Ferro Sanol® sp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
Trial: NCT02076828
Drug: Santafer® sp.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
Trial: NCT02076828
Drug: Ferro Zinc® sp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
Trial: NCT04564612
Drug: BIIB091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT01218100
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
Trial: NCT02093429
Drug: INCB047986
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB047986 will be supplied as tablets.
Trial: NCT04059523
Drug: S6G5T-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT04059523
Drug: Retin-A® 0.1% Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT02952963
Drug: Chenodeoxycholic Acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02178813
Drug: Administration of minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of minocycline with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o.
Trial: NCT00444704
Drug: PRA-027
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00904618
Drug: Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
Trial: NCT00413920
Drug: Enteric-coated mycophenolate sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
Trial: NCT01244581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mixture in two daily doses for 7 days
Trial: NCT03663374
Drug: Odelepan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, 125 mg
Trial: NCT03663374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
Trial: NCT05058105
Drug: FL058 1000mg（ IV 120min）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 qd;
Trial: NCT05058105
Drug: FL058 Placebo （ IV 120min）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 qd;
Trial: NCT01185964
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
Trial: NCT04897919
Drug: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
RxNorm normalized name: artemether-lumefantrine 20 mg-120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-Lumefantrine is given as recommended by manufacturer
Trial: NCT00244348
Drug: 5 Fluorouracil (systemic)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00505037
Drug: ASP1585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00505037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04465877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching in appearance to the active drug tablets
Trial: NCT04093765
Drug: Antimalarials
RxNorm normalized name: ANTIMALARIALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~* The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~* Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~* Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~* Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~* Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary.
Trial: NCT03958656
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
Trial: NCT03792672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-653 placebo-matching tablets.
Trial: NCT04119622
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
Trial: NCT00685646
Drug: antiandrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 24 courses of therapy
Trial: NCT00685646
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Up to 24 courses of therapy
Trial: NCT02069730
Drug: FGFR Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor
Trial: NCT02069730
Drug: Anti-androgen
RxNorm normalized name: Anti-androgens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens
Trial: NCT02069730
Drug: NOTCH Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor
Trial: NCT01564095
Drug: HTK/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
Trial: NCT02024022
Drug: Standard approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
Trial: NCT00420810
Drug: MK0928 / Duration of Treatment : 8 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03190265
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
Trial: NCT03311672
Drug: [18F]F-Ara-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
Trial: NCT02927366
Drug: Placebo Matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID
Trial: NCT00747344
Drug: Placebo - Controlled Period (CP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, Weeks 0-12
Trial: NCT00765882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Trial: NCT02562651
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline bid for the first 7 days after primary anterior STEMI
Trial: NCT01430507
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
Trial: NCT03249935
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1 gm PO single dose given as directly observed
Trial: NCT02059850
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02747342
Drug: SHR3680; SHR3162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase.
Trial: NCT03638869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02818036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02181101
Drug: FEC-DocGemzar adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02181101
Drug: FEC-Doc adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02181101
Drug: Zoledronic acid i.v. 2 years
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02181101
Drug: Zoledronic acid i.v. 5 years
FDA approved: no
EMA approved: no
PMDA approved: no